Quarterly ResultJul 23, 2026, 04:08 PM
Johnson & Johnson Q2 Sales Up 6.6% to $25.31B; Net Earnings Flat
AI Summary
Johnson & Johnson reported a 6.6% increase in second-quarter sales to $25.31 billion, with net earnings remaining largely flat at $5.53 billion. For the six months, sales grew 8.2% to $49.37 billion, while net earnings decreased significantly to $10.77 billion, primarily due to a large "other income" in the prior year. The company also highlighted risks related to the planned separation of its Orthopaedics business.
Key Highlights
- Q2 2026 sales increased 6.6% to $25.31 billion from $23.74 billion in Q2 2025.
- Q2 2026 net earnings were $5.53 billion, a slight decrease from $5.54 billion in Q2 2025.
- Diluted EPS for Q2 2026 was $2.27, down from $2.29 in Q2 2025.
- Net cash flows from operating activities for the six months ended June 28, 2026, increased to $11.13 billion from $8.05 billion.
- Total shareholders' equity rose to $84.97 billion as of June 28, 2026, from $81.54 billion at December 28, 2025.
- Repurchased $4.25 billion of common stock during the six months ended June 28, 2026.
- Goodwill totaled $48.48 billion, with $14.76 billion in Innovative Medicine and $33.72 billion in MedTech.
- Supplier finance program obligations were $0.7 billion as of June 28, 2026.
Price Impact
More from JNJ